{"prompt": "['Date and Version No: 7 19/12/19', '10.', 'SAFETY REPORTING', '10.1 Definitions', '10.1.1 Adverse Event (AE)', 'An AE or adverse experience is:', 'Any untoward medical occurrence in a patient or clinical investigation participants,', 'which does not necessarily have to have a causal relationship with this treatment.', 'An AE can therefore be any unfavourable and unintended sign (including an abnormal', 'laboratory finding), symptom or disease temporally associated with the study,', 'whether or not considered related to the study.', '10.1.2 Adverse Reaction (AR)', 'All untoward and unintended responses related to the study.', 'All cases judged by either the reporting medically qualified professional or the sponsor', 'as having a reasonable suspected causal relationship to the study qualify as adverse', 'reactions.', '10.1.3 Severe Adverse Events', 'To ensure no confusion or misunderstanding of the difference between the terms', '\"serious\" and \"severe\", which are not synonymous, the following note of clarification', 'is provided:', 'The term \"severe\" is often used to describe the intensity (severity) of a specific event', '(as in mild, moderate, or severe myocardial infarction); the event itself, however, may', 'be of relatively minor medical significance (such as severe headache). This is not', 'the same as \"serious,\" which is based on patient/event outcome or action criteria', \"usually associated with events that pose a threat to a participant's life or functioning.\", 'Seriousness (not severity) serves as a guide for defining regulatory reporting', 'obligations.', '10.1.4 Serious Adverse Event or Serious Adverse Reaction', 'A serious adverse event or reaction is any untoward medical occurrence that at any', 'dose:', 'Results in death,', 'CONFIDENTIAL', 'Page 35 of 57', 'The Cognition and Flow Study']['Date and Version No: 7 19/12/19', 'Is life-threatening,', 'NOTE: The term \"life-threatening\" in the definition of \"serious\" refers to an event in', 'which the participant was at risk of death at the time of the event; it does not refer to', 'an event which hypothetically might have caused death if it were more severe.', 'Requires inpatient hospitalisation or prolongation of existing hospitalisation,', 'Results in persistent or significant disability/incapacity, or', 'Is a congenital anomaly/birth defect.', 'Other important medical events*', '*Other events that may not result in death, are not life threatening, or do not require', 'hospitalisation, may be considered a serious adverse event when, based upon', 'appropriate medical judgement, the event may jeopardise the patient and may require', 'medical or surgical intervention to prevent one of the outcomes listed above.', '10.1.5 Expected Serious Adverse Events/Reactions', 'See Appendix D for a complete list of expected adverse events not subject to', 'immediate reporting.', '10.1.6 Suspected Unexpected Serious Adverse Reactions', 'Not applicable for this type of study.', '10.2 Reporting Procedures for All Adverse Events', 'All AEs occurring during the study observed by the investigator or reported by the', 'participant, whether or not attributed to study, will be recorded on the CRF.', 'The following information will be recorded: description, date of onset and end date,', 'severity, assessment of relatedness to study, other suspect device and action taken.', 'Follow-up information should be provided as necessary.', 'AEs considered related to the study as judged by a medically qualified investigator or', 'the sponsor will be followed until resolution or the event is considered stable. All', \"related AEs that result in a participant's withdrawal from the study or are present at\", 'the end of the study, should be followed up until a satisfactory resolution occurs.', \"It will be left to the investigator's clinical judgment whether or not an AE is of sufficient\", \"severity to require the participant's removal from the study. A participant may also\", 'CONFIDENTIAL', 'Page 36 of 57', 'The Cognition and Flow Study']['Date and Version No: 7 19/12/19', 'voluntarily withdraw from the study due to what he or she perceives as an intolerable', 'AE.', 'The severity of events will be assessed on the following scale: 1 = mild, 2 = moderate,', '3 = severe.', 'The relationship of AEs to the study will be assessed by a medically qualified', 'investigator.', '10.3 Reporting Procedures for Serious Adverse Events', 'All SAEs, except those expected ones defined in section 10.1.5 that do not require', 'immediate reporting (see 10.1.5), must be reported to the Sponsor within one working', 'day of discovery or notification of the event. The Sponsor will perform an initial check', 'of the information and ensure that it is reviewed at the next R&D Management', 'meeting. All SAE information must be recorded on an SAE form and sent to the', 'Sponsor using the appropriate reporting form and the contact details on there.', 'Additional information received for a case (follow-up or corrections to the original', 'case) needs to be detailed on a new SAE form which must be sent to the Sponsor', 'using the appropriate reporting form and the contact details on there.', 'The Sponsor will report all SUSARs to the Research Ethics Committee concerned.', 'Fatal or life-threatening SUSARs must be reported within 7 days and all other', 'SUSARs within 15 days. The CI will inform all investigators concerned of relevant', 'information about SUSARs that could adversely affect the safety of participants.', 'In addition to the expedited reporting above, the CI shall submit once a year', 'throughout the study or on request an Annual Report to the Ethics Committee which', 'lists all SAEs / SUSARs that have occurred during the preceding 12 months.', 'CONFIDENTIAL', 'Page 37 of 57', 'The Cognition and Flow Study']\n\n###\n\n", "completion": "END"}